

ABX-PF/1 DIV1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group : 1116
Applicants : Douglas Charles Hanson et al.
Application No. : 10/612,497
Confirmation No. : 3552
Filed : July 1, 2003
For : HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

New York, New York
February 11, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is a Supplemental Information Disclosure Statement
in the above-identified application. This Statement is submitted:

- ☐ within three months of the application filing date;
- ☒ more than three months from the application filing date but before
the mailing date of the first Office Action on the merits;
- ☐ before the mailing of a first Office action after the filing of a request for
continued examination;
- ☐ after the mailing date of a first Office Action on the merits but before the
mailing date of a Final Action or a Notice of Allowance.

In accordance with 37 C.F.R. § 1.97(b)(3), no fee is due in connection with this Information Disclosure Statement. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



Jane T. Gunnison (Reg. No. 38,479)
Li Su (Reg. No. 45,141)
Attorneys for Applicants
c/o FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax.: (212) 596-9090



ABX-PF1 DIV1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group Art Unit : 1116
Applicants : Douglas Charles Hanson et al.
Application No. : 10/612,497
Confirmation No. : 3552
Filed : July 1, 2003
For : HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

New York, New York
February 11, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants make of record the following documents¹:

¹ A completed Form PTO-1449 listing these documents is attached hereto.

UNITED STATES PATENT DOCUMENT

<u>Inventor</u>	<u>Patent No.</u>	<u>Issue Date</u>
Lonberg et al.	6,255,458	July 3, 2001
*Kuchroo et al.	6,207,156	March 27, 2001
Kucherlapati et al.	6,162,963	December 19, 2000
Kucherlapati et al.	6,150,584	November 21, 2002
Kucherlapati et al.	6,114,598	September 5, 2000
Allison et al.	6,051,227	April 18, 2000
Kucherlapati et al.	6,075,181	June 13, 2000
Linsley et al.	5,977,318	November 2, 1999
Linsley et al.	5,968,510	October 19, 1999
Kucherlapati et al.	5,939,598	August 17, 1999
Hori et al.	5,916,771	June 29, 1999
Allison et al.	5,855,887	January 5, 1999
Meade et al.	5,827,690	October 27, 1998
Lonberg et al.	5,814,318	September 29, 1998
Allison et al.	5,811,097	September 22, 1998
Lonberg et al.	5,789,650	August 4, 1998
Berns et al.	5,789,215	August 4, 1998
Co et al.	5,777,085	July 7, 1998
Linsley et al.	5,773,253	June 30, 1998
Lonberg et al.	5,770,429	June 23, 1998
Linsley et al.	5,770,197	June 23, 1998
Denman et al.	5,756,687	May 26, 1998
Meade et al.	5,750,172	May 12, 1998
Deboer et al.	5,741,957	April 21, 1998
Johnson et al.	5,733,743	March 31, 1998
Kay et al.	5,721,367	February 24, 1998
Co et al.	5,714,350	February 3, 1998
Johnston et al.	5,703,057	December 30, 1997
Goldenberg	5,697,902	December 16, 1997
Torii et al.	5,693,792	December 2, 1997
Queen et al.	5,693,761	December 2, 1997
Lonberg et al.	5,661,016	August 26, 1997
Buttram et al.	5,648,471	July 15, 1997
Dunn et al.	5,643,763	July 1, 1997
Lonberg et al.	5,633,425	May 27, 1997
Lonberg et al.	5,625,126	April 29, 1997
Kay et al.	5,612,205	March 18, 1997
Krimpenfort et al.	5,591,669	January 7, 1997
Queen et al.	5,585,089	December 17, 1996
Lonberg et al.	5,569,825	October 29, 1996

Surani et al.	5,545,807	August 13, 1996
Lonberg et al.	5,545,806	August 13, 1996
Queen et al.	5,530,101	June 25, 1996
Linsley et al.	5,434,131	July 18, 1995
Khawli et al.	5,194,594	March 16, 1993
Stec et al.	5,151,510	September 29, 1992
Rhodes	Re 35,500	May 6, 1997
Rhodes	5,102,990	April 7, 1992
Goldenberg	5,101,827	April 7, 1992
Clark et al.	4,959,455	September 25, 1990
Kaufman et al.	4,912,040	March 27, 1990
Boss et al.	4,816,397	March 28, 1989
Kaufman	4,740,461	April 26, 1988
Goldenberg	4,735,210	April 5, 1988
Mullis	4,683,202	July 28, 1987
Mullis et al.	4,683,195	July 28, 1987
Coates	4,681,581	July 21, 1987
Axel et al.	4,399,216	August 16, 1983
*Korman et al.	2002/0086014	July 4, 2002

FOREIGN PATENT DOCUMENTS

<u>Publication No.</u>	<u>Publication Date</u>
CA 2,205,680	November 16, 1998
EP 0 546 073	June 16, 1993
EP 0 463 151	January 2, 1992
EP 0 338 841	October 25, 1989
EP 0 323 997	July 19, 1989
EP 0 256 055	February 24, 1988
EP 0 216 846	April 8, 1987
WO 01/14424	March 1, 2001
WO 00/32231	June 8, 2000
WO 98/50433	November 12, 1998
WO 98/46996	October 22, 1998
WO 98/42752	October 1, 1998
WO 98/24893	June 11, 1998
WO 98/24884	June 11, 1998
WO 97/38137	October 16, 1997
WO 97/20574	June 12, 1997
WO 97/13852	April 17, 1997
WO 96/34096	October 31, 1996
WO 96/33735	October 31, 1996
WO 96/22380	July 25, 1996

WO 96/14436	May 17, 1996
WO 95/33770	December 14, 1995
WO 95/24217	September 14, 1995
WO 95/03408	February 2, 1995
WO 95/01994	January 19, 1995
WO 94/29444	December 22, 1994
WO 94/25585	November 10, 1994
WO 94/02602	February 3, 1994
WO 94/00569	January 6, 1994
WO 93/12227	June 24, 1993
WO 93/00431	January 7, 1993
WO 92/22670	December 23, 1992
WO 92/22647	December 23, 1992
WO 92/22645	December 23, 1992
WO 92/03918	March 19, 1992
WO 91/10741	July 25, 1991

OTHER DOCUMENTS

Alegre et al., "Regulation of surface and intracellular expression of CTLA4 on mouse T cells," *J. Immunol.*, 157:4762-4770 (1996)

Allison & Krummel, "The Yin and Yang of T cell costimulation," *Science*, 270:932-933 (1995)

Balzano et al., "CTLA-4 and CD28: Similar proteins, neighbouring genes," *Int. J. Cancer: Supplement*, 7:28-32 (1992)

Barker and Dayhoff, "Detecting distant relationships: computer methods and results," *Atlas of Protein Sequence and Structure*, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)

Blair et al., "Cutting edge: CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X_L induction," *J Immunol*, 160:12-15 (1998)

Blake and Litzi-Davis, "Evaluation of peptide libraries: An iterative strategy to analyze the reactivity of peptide mixtures with antibodies," *Bioconjugate Chem.*, 3:510-513 (1992)

Boussiotis et al., "Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation," *Proc Natl Acad Sci USA*, 90:11059-11063 (1993)

Bowie et al., "A method to identify protein sequences that fold into a known three-dimensional structure," *Science*, 253:164-170 (1991)

Bruggemann et al., "A repertoire of monoclonal antibodies with human heavy chains from transgenic mice," *PNAS USA*, 86:6709-6713 (1989)

Bruggemann and Neuberger, "Generation of antibody repertoires in transgenic mice," *Methods: A companion to Methods in Enzymology*, 2:159-165 (1991)

Bruggemann et al., "Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus," *Eur. J. Immunol.*, 21:1323-1326 (1991)

Bruggemann and Neuberger, "Strategies for expressing human antibody repertoires in transgenic mice," *Immunology Today*, 17:391-397 (1996)

Brunet et al., "A new member of the immunoglobulin superfamily - CTLA-4," *Nature*, 328:267-270 (1987)

Bumpers et al., "Consistent hepatic metastasis of human colorectal cancer in severe combined immunodeficient mice," *J. Surgical Res.*, 61:282-288 (1996)

Castan et al., "Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues," *Immunology*, 90:265-271 (1997)

Chen et al., "Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules Cd28 and CTLA-4," *Cell*, 71:1093-1102 (1992)

Chen et al., "Immunoglobulin gene rearrangement in B-cell deficient mice generated by targeted deletion of the J_H locus," *International Immunology*, 5:647-656 (1993)

Chen et al., "Intracellular antibodies as a new class of therapeutic molecules for gene therapy," *Human Gene Therapy*, 5:595-601 (1994)

Chiswell and McCafferty, "Phage antibodies: will new 'coliclonal' antibodies replace monoclonal antibodies?" *TIBTECH*, 10:80-84 (1992)

Choi et al., "Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome," *Nature Genetics*, 4:117-123 (1993)

Chothia & Lesk, "Canonical structures for the hypervariable regions of immunoglobulins," *J. Mol. Biol.*, 196:901-917 (1987)

Chothia et al., "Conformations of immunoglobulin hypervariable regions," *Nature*, 342:877-883 (1989)

Chuang et al., "Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression," *J. Immunol.*, 159:144-151 (1997)

- Coligan et al., "Unit 2.1, "Enzyme-linked immunosorbent assays," *Current Protocols in Immunology*, 2.1.1-2.1.22 (1994)
- Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands," *PNAS USA*, 87:6378-6382 (1990)
- Dariavach et al., "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains," *Eur. J. Immunol.*, 18:1901-1905 (1988)
- Dayhoff, "Survey of new data and computer methods of analysis," *Atlas of Protein Sequence and Structure*, pp. 1-10 (Volume 5, Supplement 2, National Biomedical Research Foundation (1976))
- de Boer et al., "Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells," *Eur J Immunol*, 23:3120-3125 (1993)
- Evans et al., "Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists," *J. Med. Chem.*, 30:1229-1239 (1987)
- Fallarino et al., "B7-1 Engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28," *J Exp Med*, 188:205-210 (1998)
- Fanger et al., "Production and use of anti-FcR bispecific antibodies," *ImmunoMethods*, 4:72-81 (1994)
- Fauchere, "Elements for the rational design of peptide drugs," *Adv. Drug Res.*, 15:29-69 (1986)
- Fishwild et al., "High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice," *Nature Biotech.*, 14:845-851 (1996)
- Foster et al., "Molecular Mechanisms and Selective Influences That Shape the Kappa Gene Repertoire of IgM⁺ B Cells," *J. Clin. Invest.*: 99, No. 7:1614-1627 (1997)
- Freeman et al., "Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production," *J Exp Med.*, 178:2185-2192 (1993)
- Freeman et al., "Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice," *Science*, 262:907-909 (1993)
- Freeman et al., "The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor," *J Immunol*, 161:2708-2715 (1998)

- Fry et al., "Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor," *Proc Nat'l Acad Sci USA*, 95:12022-12027 (1998)
- Furet et al., "Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411," *Journal of Computer-Aided Molecular Design*, 9:465-472 (1995)
- Galfré and Milstein, "Preparation of monoclonal antibodies: strategies and procedures." *Methods Enzymol.*, 73:3-46 (1981)
- Ginalski et al., "Modelling of active forms of protein kinases: p38 - a case study," *Acta Biochimica Polonica*, 44:557-564 (1997)
- Gorman et al., "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," *Proc Nat'l Acad Sci USA*, 79:6777-6781 (1982)
- Green and Jakobovits, "Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes," *J. Exp. Med.*, 188:483-495 (1998)
- Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," *Nature Genetics*, 7:13-21 (1994)
- *Gribben et al., "CTLA4 mediates antigen-specific apoptosis of human T cells," *Proc. Natl. Acad. Sci.*, 92:811-815 (1995)
- Grosschedl and Baltimore, "Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements," *Cell*, 41:885-897(1985)
- Hanes and Plückthun, "*In vitro* selection and evolution of functional proteins by using ribosome display," *Proc Nat'l Acad Sci USA*, 94:4937-4942 (1997)
- Harding et al., "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," *Nature*, 356:607-609 (1992)
- Harper et al., "CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location," *J Immunol*, 147:1037-1044 (1991)
- Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," *Science*, 262:905-907 (1993)

- Hofmann et al., "A model of Cdc25 phosphatase catalytic Domain and Cdk-interaction surface based on the presence of a rhodanese homology domain," *J Mol Biol*, 282:195-208 (1998)
- Holliger et al., "'Diabodies': Small bivalent and bispecific antibody fragments," *PNAS USA* 90:6444-6448 (1993)
- Hoogenboom et al., "Building antibodies from their genes," *Immunol. Reviews*, 130:43-68 (1992)
- Horspool et al., "Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4," *J Immunol*, 160:2706-2714 (1998)
- Houghten et al., "The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides," *BioTechniques*, 13:412-421 (1992)
- Houghten, "General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids," *Proc Nat'l Acad Sci USA*, 82:5131-5135 (1985)
- Hurwitz et al., "Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis," *J Neuroimmunol*, 73:57-62 (1997)
- Hurwitz et al., "CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma," *Proc Natl Acad Sci USA*, 95:10067-10071 (1998)
- Ill et al., "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions," *Protein Engineering*, 10:949-957 (1997)
- Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial-chromosome." *Nature*, 362:255-258 (1993)
- Jakobovits et al., "Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production." *Proc. Natl. Acad. Sci. USA*, 90:2551-2555 (1993)
- Jakobovits, "Humanizing the mouse genome." *Current Biology*, 4:761-763 (1994)
- Jakobovits, "Production of fully human antibodies by transgenic mice." *Current Opinion in Biotechnology*, 6:561-566 (1995)
- Jakobovits, "The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice," *Expert Opinion on Investigational Drugs*, 7:607-614 (1998)

- Joukov et al., "Identification of Csk tyrosine phosphorylation sites and a tyrosine residue important for kinase domain structure," *Biochem J*, 322:927-935 (1997)
- Junghans et al. in *Cancer Chemotherapy and Biotherapy*, 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996))
- Kostelny et al., "Formation of a bispecific antibody by the use of leucine zippers," *J. Immunol.*, 148:1547-1553 (1992)
- Krummel and Allison, "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," *J Exp Med*, 182:459-465 (1995)
- Krummel et al., "Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo," *Int Immunol*, 8:519-523 (1996)
- Kuchroo et al., "B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy," *Cell*, 80:707-718 (1995)
- Kwon et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer," *Proc Nat'l Acad Sci USA*, 94:8099-80103 (1997)
- LaPlanche et al., "Phosphorothioate-modified oligodeoxyribonucleotides. III NMR and UV spectroscopic studies of the R_p-R_p, S_p-S_p duplexes. [d(GG_s AATTCC)]₂, derived from diastereomeric O-ethyl phosphorothioates," *Nucl. Acids Res.*, 14:9081-9093 (1986)
- Lenschow et al., "Expression and functional significance of an additional ligand for CTLA-4," *Proc Nat'l Acad Sci USA*, 90:11054-11058 (1993)
- Lenschow et al., "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg," *Science*, 257:789-792 (1992)
- *"Leucocyte Typing VI: White Cell Differentiation Antigens," *Garland Publishing*, New York, NY, pp 30-31, 95-98 and 1213-1214
- Lin et al., "Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28," *J Exp Med*, 188:199-204 (1998)
- Linsley et al., "CTLA-4 is a second receptor for the B cell activation antigen B7," *J. Exp. Med.*, 174:561-569 (1991)
- Linsley et al., "Coexpression and functional cooperation of CTLA-4 and CD-28 on activated T lymphocytes," *J Exp Med*, 176:1595-1604 (1992)

- Linsley et al., "Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule," *Science*, 257:792-795 (1992)
- Liu et al., "Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity," *J. Immunol.*, 139:3521-3526 (1987)
- Liu et al., "Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells," *Proc Nat'l Acad Sci USA*, 84:3439-3443 (1987)
- Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," *Nature*, 368:856-859 (1994)
- Luhder et al., "Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes," *J Exp Med*, 187:427-432 (1998)
- Mandal et al., "ABGEN: A knowledge-based automated approach for antibody structure modeling," *Nature Biotechnology*, 14:323-328 (1996)
- Marasco, "Intrabodies: turning the humoral immune system outside in for intracellular immunization," *Gene Therapy*, 4:11-15 (1997)
- Markees et al., "Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4," *J Clin Invest*, 101:2446-2455 (1998)
- Marks et al., "Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes," *Eur. J. Immunol.*, 21:985-991 (1991)
- Marrack et al., "The Staphylococcal Enterotoxins and Their Relatives," *Science*, 705-711 (1990)
- Martin et al., "The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6," *The EMBO Journal*, 13:5303-5309 (1994)
- McCoy et al., "Protective immunity to nematode infection is induced by CTLA-4 blockade," *J Exp Med*, 186:183-187 (1997)
- Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," *Nature Genetics*, 15:146-156 (1997)
- Monfardini et al. "Rational design, analysis, and potential utility of GM-CSF antagonists," *Proc Assoc Am Physicians*, 108:420-431 (1996)

- Murphy et al., "Blockade of CTLA-4 enhances host resistance to the intercellular pathogen, *Leishmania donovani*," *J. Immunol.*, 161:4153-4160 (1998)
- Needleman and Wunsch, "A general method applicable to the search for similarities in the amino acid sequence to two proteins," *Mol. Biol.*, 48:443-453 (1970)
- Okayama et al., "A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells," *Mol. Cell. Bio.*, 3:280-289 (1983)
- Parmley and Smith, "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes," *Gene*, 73:305-318 (1988)
- Pearson and Lipman, "Improved tools for biological sequence comparison," *Proc. Natl. Acad. Sci. U.S.A.*, 85:2444-2448 (1988)
- Perez et al., "Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement," *Immunity*, 6:411-417 (1997)
- Perrin et al., "B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis," *Immunol Res*, 14:189-199 (1995)
- Perrin et al. "CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis *J Immunol*, 157:1333-1336 (1996)
- Pinilla et al., "Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries," *Biotechniques*, 13:901-905 (1992)
- Powell et al., "Compendium of excipients for parenteral formulations," *PDA J Pharm Sci Technol.* 52:238-311 (1998)
- Razi-Wolf et al., "Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor," *Proc Natl Acad Sci USA*, 90:11182-11186 (1993)
- Rizo and Gierasch, "Constrained peptides: models of bioactive peptides and protein substructures," *Annu. Rev. Biochem.*, 61:387-418 (1992)
- Russel et al., "Retroviral vectors displaying functional antibody fragments," *Nucl. Acids Research*, 21:1081-1085 (1993)
- Schwartz, "Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," *Cell*, 71:1065-1068 (1992)
- Scott, "Discovering peptide ligands using epitope libraries," *Trends in Biochemical Sciences*, 17:241-245 (1992)

Singh et al., "Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases," *J Med Chem*, 40:1130-1135 (1997)

Smith and Waterman, "Comparison of Biosequences," *Adv. Appl. Math.*, 2:482-489 (1981)

Songsivilai and Lachmann, "Bispecific antibody: a tool for diagnosis and treatment of disease," *Clin. Exp. Immunol.*, 79: 315-321 (1990)

Stec et al., "Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides," *J. Am. Chem. Soc.*, 106:6077-6079 (1984)

Stein et al., "Physicochemical properties of phosphorothioate oligodeoxynucleotides," *Nucl. Acids Res.*, 16:3209-3221 (1988)

Taylor et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins," *Nucleic Acids Research*, 20:6287-6295 (1992)

Taylor et al., "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM," *International Immunology*, 6:579-591 (1994)

Thornton et al., "Prediction of progress at last" *Nature*, 354:105-106 (1991)

Tivol et al., "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4," *Immunity*, 3:541-547 (1995)

Townsend and Allison, "Tumor rejection after direct costimulation of CD8⁺ T cells by B7-transfected melanoma cells," *Science*, 259:368-370 (1993)

Traunecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," *EMBO J*, 10:3655-3659 (1991)

Traunecker et al., "Janusin: new molecular design for bispecific reagents," *Int. J. Cancer (Suppl.)*, 7:51-52 (1992)

Tuaillon et al., "Analysis of direct and inverted DJ_H rearrangements in a human Ig heavy chain transgenic minilocus," *J. Immunol.*, 154:6453-6465 (1995)

Tuaillon et al., "Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in μ and γ transcripts," *Proc. Natl. Acad. Sci. USA*, 90:3720-3724 (1993)

Uhlmann and Peyman, "Antisense RNA: A natural gene expression control system," *Chemical Reviews*, 90:543-584 (1990)

Van Parijs et al., "Role of interleukin 12 and costimulators in T cell anergy in vivo," *The Journal of Experimental Medicine*, 186, 1119-1128 (1997)

Veber and Freidinger, "The design of metabolically-stable peptide analogs," *Trends In Neuro Sciences*, pp. 392-396 (1985)

Vitetta et al., "Immunotoxins: magic bullets or misguided missiles," *Immunol Today*, 14:252-259 (1993)

Walunas et al., "CTLA-4 can function as a negative regulator of T cell activation," *Immunity*, 1:405-413 (1994)

Walunas et al., "CTLA-4 ligation blocks CD28-dependent T cell activation," *J Exp Med*, 183:2541-2550 (1996)

Waterhouse et al., "Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4," *Science*, 270:985-988 (1995)

Winter and Harris, "Humanized Antibodies," *Immunol Today*, 14:243-246 (1993)

Wright et al., "Genetically engineered antibodies: Progress and prospects," *Crit. Reviews in Immunol.*, 12:125-168 (1992)

Yang et al., "Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages," *Cancer Res*, 57:4036-4041 (1997)

Yi-qun et al., "Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens," *Int Immunol*, 8:37-44 (1996)

Zon et al., "Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions," *Anti-Cancer Drug Design*, 6:539-568 (1991)

Zon et al., "Phosphorothioate oligonucleotides," *Oligonucleotides and Analogues: A Practical Approach*, pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991))

All documents cited herein were either previously submitted by applicants in an Information Disclosure Statement or cited by the Examiner in parent U.S. Application No.

09/472,087 ("the parent application"), from which the above-identified application claims priority. Pursuant to 37 C.F.R. § 1.98(d), applicants have not enclosed copies of the documents. However, applicants stand ready to provide copies at the Examiner's request. Documents marked by a "*" were previously cited by the Examiner in the parent application.

Applicants further request that the cited documents be (1) fully considered by the Examiner during the course of examination of this application, and (2) printed on any patent issuing from this application. Additionally, applicants request that a copy of Form PTO-1449, as considered and initialed by the Examiner, be returned with the next communication.

Respectfully submitted,



Jane T. Gunnison (Reg. No. 38,479)
Li Su (Reg. No. 45,141)
Attorneys for Applicants
c/o FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax.: (212) 596-9090



PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTSATTY. DOCKET NO.
ABX-PF1 DIV1APPLICATION NO.
10/612,497APPLICANTS
Douglas C. Hanson et al.CONFIRMATION NO.
3552FILING DATE
July 1, 2003GROUP
1116


U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,255,458	07/03/01	Lonberg et al.	530	388.15	
	6,207,156	03/27/01	Kuchroo et al.	424	154.1	
	6,162,963	12/19/00	Kucherlapati et al.	800	18	
	6,150,584	11/21/00	Kucherlapati et al.	800	18	
	6,114,598	09/05/00	Kucherlapati et al.	800	18	
	6,075,181	06/13/00	Kucherlapati et al.	800	25	
	6,051,227	04/18/00	Allison et al.	424	144.1	
	5,977,318	11/02/99	Linsley et al.	530	388.1	
	5,968,510	10/19/99	Linsley et al.	424	141.1	
	5,939,598	08/17/99	Kucherlapati et al.	800	25	
	5,916,771	06/29/99	Hori et al.	435	69.6	
	5,855,887	01/05/99	Allison et al.	424	144.1	
	5,827,690	10/27/98	Meade et al.	435	69.6	
	5,814,318	09/29/98	Lonberg et al.	424	184.1	
	5,811,097	09/22/98	Allison et al.	424	144.1	
	5,789,650	08/04/98	Lonberg et al.	800	2	
	5,789,215	08/04/98	Berns et al.	435	172.3	
	5,777,085	07/07/98	Co et al.	530	388.23	
	5,773,253	06/30/98	Linsley et al.	435	69.7	
	5,770,429	06/23/98	Lonberg et al.	435	240.2	
	5,770,197	06/23/98	Linsley et al.	424	134.1	
	5,756,687	05/26/98	Denman et al.	530	412	
	5,750,172	05/12/98	Meade et al.	426	580	
	5,741,957	04/21/98	Deboer et al.	800	2	
	5,733,743	03/31/98	Johnson et al.	435	69.1	
	5,721,367	02/24/98	Kay et al.	800	2	
	5,714,350	02/03/98	Co et al.	435	69.6	
	5,703,057	12/30/97	Johnston et al.	514	44	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTS

ATTY. DOCKET NO.
ABX-PF1 DIV1

APPLICATION NO.
10/612,497

APPLICANTS
Douglas C. Hanson et al.

CONFIRMATION NO.
3552

FILING DATE
July 1, 2003


GROUP
1116

	5,697,902	12/16/97	Goldenberg	604	49	
	5,693,792	12/02/97	Torii et al.	540	358	
	5,693,761	12/02/97	Queen et al.	536	23.53	
	5,661,016	08/26/97	Lonberg et al.	435	172.3	
	5,648,471	07/15/97	Buttram et al.	424	1.49	
	5,643,763	07/01/97	Dunn et al.	435	91.1	
	5,633,425	05/27/97	Lonberg et al.	800	2	
	5,625,126	04/29/97	Lonberg et al.	800	2	
	5,612,205	03/18/97	Kay et al.	435	172.3	
	5,591,669	01/07/97	Krimpenfort et al.	800	2	
	5,585,089	12/17/96	Queen et al.	424	133.1	
	5,569,825	10/29/96	Lonberg et al.	800	2	
	5,545,807	08/13/96	Surani et al.	800	2	
	5,545,806	08/13/96	Lonberg et al.	800	2	
	5,530,101	06/25/96	Queen et al.	530	387.2	
	5,434,131	07/18/95	Linsley et al.	514	2	
	5,194,594	03/16/93	Khawli et al.	530	391.5	
	5,151,510	09/29/92	Stec et al.	536	27	
	RE 35,500	05/06/97	Rhodes	424	1.49	
	5,102,990	04/07/93	Rhodes	530	391.5	
	5,101,827	04/07/92	Goldenberg	128	653.4	
	4,959,455	09/25/90	Clark et al.	530	351	
	4,921,040	03/27/90	Kaufman et al.	435	69.6	
	4,816,397	03/28/89	Boss et al.	435	68	
	4,740,461	04/26/88	Kaufman	435	68	
	4,735,210	04/05/88	Goldenberg	128	654	
	4,683,202	07/28/87	Mullis	435	91	
	4,683,195	07/28/87	Mullis et al.	435	6	
	4,681,581	07/21/87	Coates	604	391	
	4,399,216	08/16/83	Axel et al.	435	6	
	2002/0086014	07/04/02	Korman et al.	424	144.1	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTSATTY. DOCKET NO.
ABX-PF1 DIV1APPLICATION NO.
10/612,497APPLICANTS
Douglas C. Hanson et al.CONFIRMATION NO.
3552FILING DATE
July 1, 2003GROUP
1116

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	CA 2,205,680	11/16/98	Canada	A61K	38/17		
	EP 0 546 073	06/16/93	Europe	C12N	15/13		
	EP 0 463 151	01/02/92	Europe	C12N	15/00		
	EP 0 338 841	10/25/89	Europe	C12N	15/00		
	EP 0 323 997	07/19/89	Europe	C12N	15/12		
	EP 0 256 055	02/24/88	Europe	C12N	15/52		
	EP 0 216 846	04/08/87	Europe	C12N	15/00		
	WO 01/14424	03/01/01	PCT	C07K	16/00		
	WO 00/32231	06/08/00	PCT	A61K	39/395		
	WO 98/50433	11/12/98	PCT	C07K	16/28		
	WO 98/46996	10/22/98	PCT	G01N	33/53		
	WO 98/42752	10/01/98	PCT	C07K	16/28		
	WO 98/24893	06/11/98	PCT	C12N	15/00		
	WO 98/24884	06/11/98	PCT	C12N	5/00		
	WO 97/38137	10/16/97	PCT	C12Q	1/68		
	WO 97/20574	06/12/97	PCT	A61K	38/16		
	WO 97/13852	04/17/97	PCT	C12N	15/00		
	WO 96/34096	10/31/96	PCT	C12N	15/00		
	WO 96/33735	10/31/96	PCT	A61K	39/00		
	WO 96/22380	07/25/96	PCT	C12N	15/87		
	WO 96/14436	05/17/96	PCT	C12Q	1/68		
	WO 95/33770	12/14/95	PCT	C07K	14/705		
	WO 95/24217	09/14/95	PCT	A61K	39/395		
	WO 95/03408	02/02/95	PCT	C12N	15/12		
	WO 95/01994	01/19/95	PCT	C07K	14/705		
	WO 94/29444	12/22/94	PCT	C12N	15/11		
	WO 94/25585	11/10/94	PCT	C12N	15/00		
	WO 94/02602	02/03/94	PCT	C12N	15/00		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTSATTY. DOCKET NO.
ABX-PF1 DIV1APPLICATION NO.
10/612,497APPLICANTS
Douglas C. Hanson et al.CONFIRMATION NO.
3552FILING DATE
July 1, 2003GROUP
1116

	WO 94/00569	01/06/94	PCT	C12N	15/00		
	WO 93/12227	06/24/93	PCT	C12N	15/00		
	WO 93/00431	01/07/93	PCT	C12N	15/12		
	WO 92/22670	12/23/92	PCT	C12Q	1/68		
	WO 92/22647	12/23/92	PCT	C12N	15/00		
	WO 92/22645	12/23/92	PCT	C12N	15/00		
	WO 92/03918	03/19/92	PCT	A01H	1/00		
	WO 91/10741	07/25/91	PCT	C12P	21/06		


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Alegre et al., "Regulation of surface and intracellular expression of CTLA4 on mouse T cells,," <i>J. Immunol.</i> , 157:4762-4770 (1996)
	Allison & Krummel, "The Yin and Yang of T cell costimulation, " <i>Science</i> , 270:932-933 (1995)
	Balzano et al., "CTLA-4 and CD28: Similar proteins, neighbouring genes," <i>Int'l J Cancer Suppl.</i> , 7:28-32 (1992)
	Barker and Dayhoff, "Detecting distant relationships: computer methods and results," <i>Atlas of Protein Sequence and Structure</i> , pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972))
	Blair et al., "Cutting edge: CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-XL induction," <i>J Immunol</i> , 160:12-15 (1998)
	Blake and Litzi-Davis, "Evaluation of peptide libraries: An iterative strategy to analyze the reactivity of peptide mixtures with antibodies," <i>BioConjugate Chem.</i> , 3:510-513 (1992)
	Boussiotis et al., "Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation," <i>Proc Natl Acad Sci USA</i> , 90:11059-11063 (1993)
	Bowie et al., "A method to identify protein sequences that fold into a known three-dimensional structure," <i>Science</i> , 253:164-170 (1991)
	Bruggemann et al., "A repertoire of monoclonal antibodies with human heavy chains from transgenic mice," <i>PNAS USA</i> , 86:6709-6713 (1989)
	Bruggemann and Neuberger, "Generation of antibody repertoires in transgenic mice," <i>Methods: A companion to Methods in Enzymology</i> , 2:159-165 (1991)
	Bruggemann et al., "Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus," <i>Eur. J. Immunol.</i> 21:1323-1326 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTSATTY. DOCKET NO.
ABX-PF1 DIV1APPLICATION NO.
10/612,497APPLICANTS
Douglas C. Hanson et al.CONFIRMATION NO.
3552FILING DATE
July 1, 2003GROUP
1116


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Bruggemann, M. and Neuberger, M.S. "Strategies for expressing human antibody repertoires in transgenic mice," <i>Immunology Today</i> , 17:391-397 (1996)
	Brunet et al., "A new member of the immunoglobulin superfamily - CTLA-4," <i>Nature</i> , 328:267-270 (1987)
	Bumpers et al., "Consistent hepatic metastasis of human colorectal cancer in severe combined immunodeficient mice," <i>J. Surgical Res.</i> , 61:282-288 (1996)
	Castan et al., "Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues," <i>Immunology</i> , 90:265-271 (1997)
	Chen et al., "Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules Cd28 and CTLA-4," <i>Cell</i> 71:1093-1102 (1992)
	Chen et al., "Immunoglobulin gene rearrangement in B-cell deficient mice generated by targeted deletion of the JH locus," <i>International Immunology</i> , 5:647-656 (1993)
	Chen et al., "Intracellular antibodies as a new class of therapeutic molecules for gene therapy," <i>Human Gene Therapy</i> , 5:595-601 (1994)
	Chiswell and McCafferty, "Phage antibodies: will new 'coliclonal' antibodies replace monoclonal antibodies?" <i>TIBTECH</i> , 10:80-84 (1992)
	Choi et al., "Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome," <i>Nature Genetics</i> , 4:117-123 (1993)
	Chothia & Lesk, "Canonical structures for the hypervariable regions of immunoglobulins," <i>J. Mol. Biol.</i> , 196:901-917 (1987)
	Chothia et al., "Conformations of immunoglobulin hypervariable regions," <i>Nature</i> , 342:877-883 (1989)
	Chuang et al., "Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression," <i>J. Immunol.</i> , 159:144-151 (1997)
	Coligan et al., "Unit 2.1, "Enzyme-linked immunosorbent assays," <i>Current protocols in immunology</i> , 2.1.1-2.1.22 (1994)
	Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands," <i>PNAS USA</i> , 87:6378-6382 (1990)
	Dariavach et al., "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains," <i>Eur. J. Immunol.</i> , 18:1901-1905 (1988)
	Dayhoff, "Survey of new data and computer methods of analysis," <i>Atlas of Protein Sequence and Structure</i> , pp. 1-10 (Volume 5, Supplement 2, National Biomedical Research Foundation (1976))

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTSATTY. DOCKET NO.
ABX-PF1 DIV1APPLICATION NO.
10/612,497APPLICANTS
Douglas C. Hanson et al.CONFIRMATION NO.
3552FILING DATE
July 1, 2003GROUP
1116


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	de Boer et al., "Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells," <i>Eur J Immunol</i> , 23:3120-3125 (1993)
	Evans et al., "Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists," <i>J. Med. Chem.</i> , 30:1229 (1987)
	Fallarino et al., "B7-1 Engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28," <i>J Exp Med</i> , 188:205-210 (1998)
	Fanger et al., "Production and use of anti-FcR bispecific antibodies," <i>Immunol Methods</i> , 4:72-81 (1994)
	Fauchere, J., "Elements for the rational design of peptide drugs," <i>Adv. Drug Res.</i> , 15:29-69 (1986)
	Fishwild et al., "High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice," <i>Nature Biotech.</i> , 4:845-851 (1996)
	Foster et al., "Molecular Mechanisms and Selective Influences That Shape the Kappa Gene Repertoire of IgM ⁺ B Cells," <i>J. Clin. Invest.</i> , 99:1614-27 (1997).
	Freeman et al., "Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production," <i>J Exp Med.</i> , 178:2185-192 (1993)
	Freeman et al., "Uncovering of functional alternative CTLA-4 counter-receptor in B7- deficient mice," <i>Science</i> , 262:907-909 (1993)
	Freeman et al., "The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor," <i>J Immunol</i> , 161:2708-2715 (1998)
	Fry et al., "Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor," <i>Proc Nat'l Acad Sci USA</i> , 95:12022-12027 (1998)
	Furet et al., "Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411," <i>J of Computer-Aided Molecular Design</i> , 9:465-472 (1995)
	Galfre and Milstein, "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods Enzymol.</i> , 73:3-46 (1981)
	Ginalski et al., "Modelling of active forms of protein kinases: p38 - a case study," <i>Acta Biochimica Polonica</i> , 44:557-564 (1997)
	Gorman et al., "The rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," <i>Proc Nat'l Acad Sci USA</i> , 79:6777 (1982)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTSATTY. DOCKET NO.
ABX-PF1 DIV1APPLICATION NO.
10/612,497APPLICANTS
Douglas C. Hanson et al.CONFIRMATION NO.
3552FILING DATE
July 1, 2003GROUP
1116


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," <i>Nature Genetics</i> , 7:13-21 (1994)
	Green and Jakobovits, "Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes," <i>J. Exp. Med.</i> , 188:483-495 (1998)
	Gribben et al., "CTLA4 mediates antigen specific apoptosis of human T cells," <i>Proc. Natl. Acad. Sci.</i> , 92:811-815 (1995)
	Grosschedl and Baltimore, "Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements," <i>Cell</i> , 41:885-897 (1985)
	Hanes and Plückthun, "In vitro selection and evolution of functional proteins by using ribosome display," <i>Proc Nat'l Acad Sci USA</i> , 94:4937-4942 (1997)
	Harding et al., "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," <i>Nature</i> , 356:607-609 (1992)
	Harper et al., "CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location," <i>J Immunol</i> , 147:1037-1044 (1991)
	Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," <i>Science</i> , 262:905-907 (1993)
	Hofmann et al., "A model of Cdc25 phosphatase catalytic Domain and Cdk-interaction surface based on the presence of a rhodanese homology domain," <i>J Mol Biol</i> , 282:195-208 (1998)
	Holliger et al., "Diabodies: Small bivalent and bispecific antibody fragments," <i>PNAS USA</i> 90:6444-6448 (1993)
	Hoogenboom et al., "Building antibodies from their genes," <i>Immunol. Reviews</i> , 130:43-68 (1992)
	Horspool et al., "Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4," <i>J Immunol</i> , 160:2706-2714 (1998)
	Houghten, "General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids," <i>Proc Nat'l Acad Sci USA</i> , 82:5131-5135 (1985)
	Houghten et al., "The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides," <i>Biotechniques</i> , 13:412-421 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTSATTY. DOCKET NO.
ABX-PF1 DIV1APPLICATION NO.
10/612,497APPLICANTS
Douglas C. Hanson et al.CONFIRMATION NO.
3552FILING DATE
July 1, 2003GROUP
1116


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Hurwitz et al., "Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis," <i>J Neuroimmunol</i> , 73:57-62 (1997)
	Hurwitz et al., "CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma," <i>Proc Natl Acad Sci USA</i> , 95:10067-10071 (1998)
	Ill et al., "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions," <i>Protein Engineering</i> , 10:949-957 (1997)
	Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial-chromosome," <i>Nature</i> , 362:255-258 (1993)
	Jakobovits, et al., "Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production," <i>Proc. Natl. Acad. Sci. USA</i> , 90:2551-2555 (1993)
	Jakobovits, "Humanizing the mouse genome," <i>Current Biology</i> , 4:761-763 (1994)
	Jakobovits, "Production of fully human antibodies by transgenic mice," <i>Current Opinion in Biotechnology</i> , 6:561-566 (1995)
	Jakobovits, "The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice," <i>Expert Opinion on Investigational Drugs</i> , 7:607-614 (1998)
	Joukov et al., "Identification of Csk tyrosine phosphorylation sites and a tyrosine residue important for kinase domain structure," <i>Biochem J</i> , 322:927-935 (1997)
	Junghans et al., "Antibody-based immunotherapies for cancer," <i>Cancer Chemotherapy and Biotherapy</i> , 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996))
	Kostelny et al., "Formation of a bispecific antibody by the use of leucine zippers," <i>J. Immunol.</i> , 148:1547-1553 (1992)
	Krummel and Allison, "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," <i>J Exp Med</i> , 182:459-465 (1995)
	Krummel et al., "Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo," <i>Int Immunol</i> , 8:519-523 (1996)
	Kuchroo et al., "B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy," <i>Cell</i> , 80:707-718 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTSATTY. DOCKET NO.
ABX-PF1 DIV1APPLICATION NO.
10/612,497APPLICANTS
Douglas C. Hanson et al.CONFIRMATION NO.
3552FILING DATE
July 1, 2003GROUP
1116


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Kwon et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer," <i>Proc Nat'l Acad Sci USA</i> , 94:8099-8103 (1997)
	LaPlanche et al., "Phosphorothioate-modified oligodeoxyribonucleotides. III NMR and UV spectroscopic studies of the R _p -R _p , S _p -S _p duplexes. [d(GG _s AATTCC)] ₂ , derived from diastereomeric O-ethyl phosphorothioates," <i>Nucl. Acids Res.</i> , 14:9081 (1986)
	Lenschow et al., "Expression and functional significance of an additional ligand for CTLA-4," <i>Proc Nat'l Acad Sci USA</i> , 90:11054-11058 (1993)
	Lenschow et al., "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg," <i>Science</i> , 257:789-792 (1992)
	"Leucocyte Typing VI: White Cell Differentiation Antigens," <i>Garland Publishing</i> , New York, NY, pp 30-31, 95-98 and 1213-1214.
	Lin et al., "Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28," <i>J Exp Med</i> , 188:199-204 (1998)
	Linsley et al., "CTLA-4 is a second receptor for the B cell activation antigen B7," <i>J. Exp. Med.</i> , 174:561-569 (1991)
	Linsley et al., "Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes," <i>J Exp Med</i> , 176:1595-1604 (1992)
	Linsley et al., "Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule," <i>Science</i> , 257:792-795 (1992)
	Liu et al., "Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity," <i>J. Immunol.</i> , 139:3521-3526 (1987)
	Liu et al., "Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells," <i>Proc Nat'l Acad Sci USA</i> , 84:3439-3443 (1987)
	Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," <i>Nature</i> , 368:856-859 (1994)
	Lühder et al., "Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes," <i>J Exp Med</i> , 187:427-432 (1998)
	Mandal et al., "ABGEN: A knowledge-based automated approach for antibody structure modeling," <i>Nature Biotechnology</i> , 14:323-328

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTSATTY. DOCKET NO.
ABX-PF1 DIV1APPLICATION NO.
10/612,497APPLICANTS
Douglas C. Hanson et al.CONFIRMATION NO.
3552FILING DATE
July 1, 2003GROUP
1116


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Marasco, "Intrabodies: turning the humoral immune system outside in for intracellular immunization," <i>Gene Therapy</i> , 4:11-15 (1997)
	Markees et al., "Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon- γ , and CTLA4," <i>J Clin Invest</i> , 101:2446-2455 (1998)
	Marks et al., "Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes." <i>Eur. J. Immunol.</i> , 21:985-991 (1991)
	Marrack, et al., "The Staphylococcal Enterotoxins and Their Relatives," <i>Science</i> , 705-711 (1990)
	Martin et al., "The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6," <i>The EMBO Journal</i> , 13:5303-5309
	McCoy et al., "Protective immunity to nematode infection is induced by CTLA-4 blockade," <i>J Exp Med</i> , 186:183-187 (1997)
	Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," <i>Nature Genetics</i> , 15:146-156 (1997)
	Monfardini et al. "Rational design, analysis, and potential utility of GM-CSF antagonists," <i>Proc Assoc Am Physicians</i> , 108:420-431 (1996)
	Murphy et al., "Blockade of CTLA-4 enhances host resistance to the intercellular pathogen, <i>Leishmania donovani</i> ," <i>J. Immunol.</i> , 161:4153-4160 (1998)
	Needleman and Wunsch, "A general method applicable to the search for similarities in the amino acid sequence to two proteins," <i>Mol. Biol.</i> , 48:443-453 (1970)
	Okayama et al., "A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells," <i>Mol. Cell. Bio.</i> , 3:280-289 (1983)
	Parmley and Smith, "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes," <i>Gene</i> , 73:305-318 (1988)
	Pearson and Lipman, "Improved tools for biological sequence comparison," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 85:2444-2448 (1988)
	Perez et al., "Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement," <i>Immunity</i> , 6:411-417 (1997)
	Perrin et al., "B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis," <i>Immunol Res</i> , 14:189-199 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTSATTY. DOCKET NO.
ABX-PF1 DIV1APPLICATION NO.
10/612,497APPLICANTS
Douglas C. Hanson et al.CONFIRMATION NO.
3552FILING DATE
July 1, 2003GROUP
1116


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Perrin et al. "CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis" <i>J Immunol</i> , 157:1333-1336 (1996)
	Pinilla et al., "Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries," <i>Biotechniques</i> , 13:901-905 (1992)
	Powell et al., "Compendium of excipients for parenteral formulations," <i>PDA J Pharm Sci Technol</i> . 52:238-311 (1998)
	Razi-Wolf et al., "Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor," <i>Proc Natl Acad Sci USA</i> , 90:11182-11186 (1993)
	Rizo and Gierasch, "Constrained peptides: models of bioactive peptides and protein substructure," <i>Ann. Rev. Biochem.</i> , 61:387-418 (1992)
	Russel et al., "Retroviral vectors displaying functional antibody fragments," <i>Nucl. Acids Research</i> , 21:1081-1085 (1993)
	Schwartz, "Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," <i>Cell</i> , 71:1065-1068 (1992)
	Scott, "Discovery peptide ligands using epitope libraries," <i>Trends in Biochemical Sciences</i> , 17:241-245 (1992)
	Singh et al., "Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases," <i>J Med Chem</i> , 40:1130-1135 (1997)
	Smith and Waterman, "Comparison of Biosequences," <i>Adv. Appl. Math.</i> , 2:482-489 (1981)
	Songsivilai and Lachmann, "Bispecific antibody: a tool for diagnosis and treatment of disease," <i>Clin. Exp. Immunol.</i> , 79: 315-321 (1990)
	Stec et al., "Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides," <i>J. Am. Chem. Soc.</i> , 106:6077-6079 (1984)
	Stein et al., "Physicochemical properties of phosphorothioate oligodeoxynucleotides," <i>Nucl. Acids Res.</i> , 16:3209-3221 (1988)
	Taylor et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins," <i>Nucleic Acids Research</i> , 20:6287-6295 (1992)
	Taylor et al., "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM," <i>International Immunology</i> , 6:579-591 (1994)
	Thornton et al., "Prediction of progress at last" <i>Nature</i> , 354:105-106 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTSATTY. DOCKET NO.
ABX-PF1 DIV1APPLICATION NO.
10/612,497APPLICANTS
Douglas C. Hanson et al.CONFIRMATION NO.
3552FILING DATE
July 1, 2003GROUP
1116

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Tivol et al., "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4," <i>Immunity</i> , 3:541-547 (1995)
	Townsend and Allison, "Tumor rejection after direct costimulation of CD8 ⁺ T cells by B7-transfected melanoma cells," <i>Science</i> , 259:368-370 (1993)
	Traunecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," <i>EMBO J</i> , 10:3655-3659 (1991)
	Traunecker et al., "Janusin: new molecular design for bispecific reagents," <i>Int. J. Cancer (Suppl.)</i> , 7:51-52 (1992)
	Tuaillon et al., "Analysis of direct and inverted DJH rearrangements in a human Ig heavy chain transgenic minilocus," <i>J. Immunol.</i> , 154:6453-6465 (1995)
	Tuaillon et al., "Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in μ and γ transcripts," <i>Proc. Natl. Acad. Sci. USA</i> , 90:3720-3724 (1993)
	Uhlmann and Peyman, "Antisense RNA: A natural gene expression control system," <i>Chemical Reviews</i> , 90:543 (1990)
	Van Parijs et al., "Role of interleukin 12 and costimulators in T cell anergy in vivo," <i>The Journal of Experimental Medicine</i> , 186, 1119-1128 (1997)
	Veber and Freidinger, "The design of metabolically-stable peptide analogs," <i>Trends In Neuro Sciences</i> , p.392 (1985)
	Vitetta et al., "Immunotoxins: magic bullets or misguided missiles," <i>Immunol Today</i> , 14:252-259 (1993)
	Walunas et al., "CTLA-4 can function as a negative regulator of T cell activation," <i>Immunity</i> , 1:405-413 (1994)
	Walunas et al., "CTLA-4 ligation blocks CD28-dependent T cell activation," <i>J Exp Med</i> , 183:2541-2550 (1996)
	Waterhouse et al., "Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4," <i>Science</i> , 270:985-988 (1995)
	Winter and Harris, "Humanized Antibodies," <i>Immunology Today</i> , 14:243-246 (1993)
	Wright et al., "Genetically engineered antibodies: Progress and prospects," <i>Crit. Reviews in Immunol.</i> , 12:125-168 (1992)
	Yang et al., "Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages," <i>Cancer Res</i> , 57:4036-4041 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABX-PF1 DIV1APPLICATION NO.
10/612,497INFORMATION DISCLOSURE
STATEMENT BY APPLICANTSAPPLICANTS
Douglas C. Hanson et al.CONFIRMATION NO.
3552FILING DATE
July 1, 2003GROUP
1116

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Yi-qun et al., "Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens," <i>Int Immunol</i> , 8:37-44 (1996)
	Zon et al., "Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions," <i>Anti-Cancer Drug Design</i> , 6:539-568 (1991)
	Zon et al., "Phosphorothioate oligonucleotides," <i>Oligonucleotides and Analogues: A Practical Approach</i> , pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991))

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.